BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:DNA-Encoded Protein Sensing
DTSTART:20251210T090000
DTEND:20251210T100000
DTSTAMP:20260603T030630Z
UID:7853a2c281b69fa2171300ed50aab0ca7f438e8e70280ae231e47c3b
CATEGORIES:Conferences - Seminars
DESCRIPTION:Sarah E. Sandler\, Ph.D.\, Wyss Institute for Biologically Ins
 pired Engineering at Harvard University\, Boston\, MA (USA)\n2-DAY BIOE MI
 NI-SYMPOSIUM on Measurement Technologies\n(DAY ONE:  talk one / next talk
 )\n\nAbstract:\nNanopores are transforming DNA sequencing and are emerging
  as powerful tools for sensing and characterizing RNA\, peptides\, protein
 s\, metabolites and protein-DNA complexes.  By combining the single molec
 ule nanopore technology with engineered DNA nanostructures\, we can create
  powerful therapeutic and diagnostic technologies. In this talk\, I will d
 iscuss my past work using solid-state nanopores as tools for screening int
 eractions of proteins with nucleic acids for CRISPR-Cas guide design (Sand
 ler et al.\, Nature Biomedical Engineering 2023) as well as for screening 
 interactions between small molecules and proteins for developing modulator
 s of protein aggregation in neurodegeneration (Sandler\, Horne et al.\, JA
 CS\, 2024\, Sandler\, Horne et al. Nature Reviews Chemistry 2025). Beyond 
 screening approaches\, the two techniques\, DNA nanotechnology and nanopor
 e sensing\, are also powerful tools in the space of diagnostics. I have de
 monstrated this both for neurodegenerative biomarkers as well as biomarker
 s for infectious disease using two different approaches. One approach\, su
 ccessive proximity extension amplification reaction (SPEAR)\, developed in
  the Yin group\, is capable of sensing sub-femtomolar concentrations of pr
 oteins from only 1 µL of sample with a qPCR read out. The other approach\
 , which I developed in the Keyser group at the University of Cambridge\, i
 nvolves engineering DNA-RNA nanostructures to act as highly specific biose
 nsors with single nucleotide resolution for detecting a variety of RNA of 
 different sizes and identities\, without the need for amplification. By co
 mbining DNA nanotechnology and nanopore sensing we can engineer platforms 
 capable of screening interactions between proteins and their targets as we
 ll as detecting biomarkers all in a multiplexed manner.\n\nBio:\nDr. Sarah
  Sandler is currently a post-doctoral research fellow at the Wyss Institut
 e for Biologically Inspired Engineering at Harvard University in the Yin g
 roup. She holds a B.S. from Clemson University in Materials Science and En
 gineering with a polymeric material focus and minors in Microbiology\, Int
 ernational Science and Engineering. Following her time at Clemson\, she mo
 ved to the University of Cambridge in the UK\, where she received her Mast
 er’s degree in Nanoscience and Nanotechnology as well as her PhD in Phys
 ics in the Keyser group\, which was funded by Oxford Nanopore Technologies
 . She is the founder of NanoDEX\, a start-up leveraging nanopore technolog
 y for therapeutic applications.\n\n\nZoom link for attending remotely\, if
  needed: https://epfl.zoom.us/j/66947851573
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717 https://epfl.zoom.u
 s/j/66947851573
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR